Exchange: OTC Sector: Healthcare Industry: Medical Instruments & Supplies
18.26% $0.590
America/New_York / 3 mai 2024 @ 15:51
FUNDAMENTALS | |
---|---|
MarketCap: | 70.69 mill |
EPS: | -0.0100 |
P/E: | -59.00 |
Earnings Date: | Apr 12, 2024 |
SharesOutstanding: | 119.82 mill |
Avg Daily Volume: | 0.0256 mill |
RATING 2024-05-03 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -59.00 | sector: PE 29.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.72x |
Company: PE -59.00 | industry: PE 34.33 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0052 (-100.88%) $-0.595 |
Date: 2024-05-05 |
Expected Trading Range (DAY) |
---|
$ 0.521 - 0.659 ( +/- 11.69%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-09 | Liu Lina | Sell | 4 728 000 | Class A Common Stock |
2022-09-23 | Focus Draw Group Ltd | Sell | 4 728 000 | Class A Common Stock |
2021-01-14 | Chinaone Technology Ltd | Sell | 0 | Class A Common Stock |
2021-01-14 | Flydragon International Ltd | Sell | 0 | Class A Common Stock |
2021-01-14 | Focus Draw Group Ltd | Sell | 0 | Class A Common Stock |
INSIDER POWER |
---|
-100.00 |
Last 21 transactions |
Buy: 76 509 252 | Sell: 127 803 438 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.590 (18.26% ) |
Volume | 0.0319 mill |
Avg. Vol. | 0.0256 mill |
% of Avg. Vol | 124.33 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Yubo International Biotech Limited, thorough its subsidiaries, focuses on the research and development, and application of endometrial stem cells. It offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting services under the VIVCELL brand. The company is based in Beijing, China.